Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hallvard Holdaas

Showing results (1-10 of 156) with videos related to

Pageof 16
Sort By:
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|June 30, 2005
Preventing cardiovascular outcome in patients with renal impairment: is there a role for lipid-lowering therapy?Hallvard Holdaas
Transplantation|July 27, 2019
People in TransplantationHallvard Holdaas
European Heart Journal|February 16, 2008
Statin therapy for prevention of coronary artery disease. The earlier the better or the longer the better?Hallvard Holdaas
Kidney International|April 15, 2017
Regarding "Obesity increases the risk of end-stage renal disease among living kidney donors"Geir Mjøen, Hallvard Holdaas
Nature Reviews. Nephrology|October 24, 2012
Chronic kidney disease: Do patients with CKD benefit from lipid-lowering therapy?Hallvard Holdaas, Alan Jardine
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 31, 2002
The use of statins after solid organ transplantationHallvard Holdaas, Desmond Julian
Expert Review of Cardiovascular Therapy|September 8, 2004
Fluvastatin and fluvastatin extended release: a clinical and safety profileAnders Asberg, Hallvard Holdaas
Kidney International|February 28, 2015
The authors reply:Geir Mjøen, Hallvard Holdaas
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|November 7, 2006
[A renaissance for home hemodialysis?]Hallvard Holdaas, Lars Westlie
BMJ (Clinical Research Ed.)|April 27, 2017
Long term risk of mortality after living kidney donationGeir Mjøen, Hallvard Holdaas
Pageof 16

Showing results (1-10 of 156) with videos related to

Sort By:
Pageof 16
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|June 30, 2005
Preventing cardiovascular outcome in patients with renal impairment: is there a role for lipid-lowering therapy?Hallvard Holdaas
Transplantation|July 27, 2019
People in TransplantationHallvard Holdaas
European Heart Journal|February 16, 2008
Statin therapy for prevention of coronary artery disease. The earlier the better or the longer the better?Hallvard Holdaas
Kidney International|April 15, 2017
Regarding "Obesity increases the risk of end-stage renal disease among living kidney donors"Geir Mjøen, Hallvard Holdaas
Nature Reviews. Nephrology|October 24, 2012
Chronic kidney disease: Do patients with CKD benefit from lipid-lowering therapy?Hallvard Holdaas, Alan Jardine
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 31, 2002
The use of statins after solid organ transplantationHallvard Holdaas, Desmond Julian
Expert Review of Cardiovascular Therapy|September 8, 2004
Fluvastatin and fluvastatin extended release: a clinical and safety profileAnders Asberg, Hallvard Holdaas
Kidney International|February 28, 2015
The authors reply:Geir Mjøen, Hallvard Holdaas
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|November 7, 2006
[A renaissance for home hemodialysis?]Hallvard Holdaas, Lars Westlie
BMJ (Clinical Research Ed.)|April 27, 2017
Long term risk of mortality after living kidney donationGeir Mjøen, Hallvard Holdaas
Pageof 16